Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 22'nd Oct 2024
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Attractive Biotechs With Recent Positives
04:17pm, Monday, 21'st Oct 2024
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:46am, Monday, 21'st Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
12:45pm, Friday, 18'th Oct 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the
Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
04:41am, Friday, 18'th Oct 2024
Exelixis' stock has surged 51% since July 2023, significantly outperforming broader markets and breaking out of a five-year stagnation. Cabometyx, EXEL's primary revenue driver, continues to excel in
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
12:06pm, Wednesday, 16'th Oct 2024
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
10:51am, Wednesday, 16'th Oct 2024
The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
04:05pm, Tuesday, 15'th Oct 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
01:57pm, Tuesday, 15'th Oct 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-002
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
10:00am, Tuesday, 15'th Oct 2024
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
ALAMEDA, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have ente
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
11:26am, Monday, 07'th Oct 2024
EXEL stock surges 20.7% on encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for growth.
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 02'nd Oct 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more a
2 Growth Stocks to Buy With Less Than $100
08:45am, Thursday, 26'th Sep 2024
With e-commerce accounting for just 16% of U.S. retail sales, Shopify has plenty of runway ahead. Exelixis is an innovative drugmaker focusing on one of the most competitive areas in the industry.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:56am, Friday, 20'th Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
